Relative survival following response to 7 + 3 versus azacytidine is similar in acute myeloid leukemia and high-risk myelodysplastic syndromes: an analysis of four SWOG studies.
| dc.contributor.author | Othus, Megan | |
| dc.contributor.author | Sekeres, Mikkael A | |
| dc.contributor.author | Nand, Sucha | |
| dc.contributor.author | Garcia-Manero, Guillermo | |
| dc.contributor.author | Appelbaum, Frederick R | |
| dc.contributor.author | Erba, Harry P | |
| dc.contributor.author | Estey, Eli | |
| dc.date.accessioned | 2019-12-01T17:46:55Z | |
| dc.date.available | 2019-12-01T17:46:55Z | |
| dc.date.issued | 2019-02 | |
| dc.date.updated | 2019-12-01T17:46:54Z | |
| dc.description.abstract | Here we quantify and compare the absolute and relative overall survival (OS) benefits conveyed by complete remission (CR) in AML and high-risk MDS, and by CR with incomplete count recovery (CRi) in AML and by hematologic improvement (HI) in MDS, following treatment with 7 + 3 versus azacytidine. We compared patients receiving 7 + 3 in SWOG studies S0106 (n = 301) and S1203 (n = 261) enrolling adults ≤ 60 years, with patients receiving azacytidine therapies in S0703 (n = 133 AML patients ≥ 60) and S1117 (n = 277 MDS patients ≥ 18). Absolute survival benefit was evaluated with 1-year, 3-year, and median OS; relative benefit was evaluated with univariate and covariate-adjusted hazard ratios. CR conveyed a relative survival advantage in multivariable analysis, with a similar relative effect of CR across studies. CR also conferred an absolute survival benefit, but with a smaller magnitude of absolute benefit in the azacytidine trials. In AML, OS was similar for CRi and failure to achieve CR/CRi. In MDS, CR conferred a survival advantage versus HI and HI versus failure. The relative survival benefit of CR was similar regardless of initial therapy for AML or high-risk MDS. With both therapies, CR has a beneficial effect on survival compared with CRi or HI. | |
| dc.identifier | 10.1038/s41375-018-0275-x | |
| dc.identifier.issn | 0887-6924 | |
| dc.identifier.issn | 1476-5551 | |
| dc.identifier.uri | ||
| dc.language | eng | |
| dc.publisher | Springer Science and Business Media LLC | |
| dc.relation.ispartof | Leukemia | |
| dc.relation.isversionof | 10.1038/s41375-018-0275-x | |
| dc.subject | Humans | |
| dc.subject | Myelodysplastic Syndromes | |
| dc.subject | Azacitidine | |
| dc.subject | Aminoglycosides | |
| dc.subject | Cytarabine | |
| dc.subject | Antineoplastic Combined Chemotherapy Protocols | |
| dc.subject | Treatment Outcome | |
| dc.subject | Remission Induction | |
| dc.subject | Survival Rate | |
| dc.subject | Risk Factors | |
| dc.subject | Follow-Up Studies | |
| dc.subject | Adolescent | |
| dc.subject | Adult | |
| dc.subject | Aged | |
| dc.subject | Aged, 80 and over | |
| dc.subject | Middle Aged | |
| dc.subject | Female | |
| dc.subject | Male | |
| dc.subject | Clinical Trials as Topic | |
| dc.subject | Leukemia, Myeloid, Acute | |
| dc.subject | Young Adult | |
| dc.subject | Antibodies, Monoclonal, Humanized | |
| dc.title | Relative survival following response to 7 + 3 versus azacytidine is similar in acute myeloid leukemia and high-risk myelodysplastic syndromes: an analysis of four SWOG studies. | |
| dc.type | Journal article | |
| duke.contributor.orcid | Erba, Harry P|0000-0003-1093-2189 | |
| pubs.begin-page | 371 | |
| pubs.end-page | 378 | |
| pubs.issue | 2 | |
| pubs.organisational-group | School of Medicine | |
| pubs.organisational-group | Duke | |
| pubs.organisational-group | Duke Cancer Institute | |
| pubs.organisational-group | Institutes and Centers | |
| pubs.publication-status | Published | |
| pubs.volume | 33 |
Files
Original bundle
- Name:
- Relative survival following response to 7 3 versus azacytidine is similar in acute myeloid leukemia and high-risk myelodysplastic syndromes: an analysis of four SWOG studies.pdf
- Size:
- 381.31 KB
- Format:
- Adobe Portable Document Format